Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. LEMTRADA
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

LEMTRADA

Medicine - Posted on Oct 25 2018 - Updated on Jun 12 2019
Active substance (DCI)
  • alemtuzumab
history (3)
  • 10/3/18

    LEMTRADA (alemtuzumab)

    LEMTRADA (alemtuzumab)
    CAV :
    54321
    icône flèche
  • Economic analysis
    1/6/16

    LEMTRADA (alemtuzumab), selective immunosuppressant

    No clinical benefit demonstrated in the treatment of multiple sclerosis. LEMTRADA has a Marketing Authorisation in adults wi...
    CAV :
    54321
    icône flèche
  • 10/25/17

    LEMTRADA (alemtuzumab)

    LEMTRADA (alemtuzumab)
    icône flèche
Technical information
ATC code
  • L04AA34
Manufacturer
SANOFI-AVENTIS FRANCE
Presentation

LEMTRADA 12 mg, solution à diluer pour perfusion (code CIS : 60779773) 1 flacon(s) en verre - Code CIP : 3400958567346

All our publications
    Autoimmune diseases Central nervous system diseases Demyelinating diseases Drug therapy Health economics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
tRQtsTSSwKEKHYTZ